Sun Pharmaceutical Industries Ltd. closed 14.89% short of its 52-week high of 1,960.20 rupees, which the company achieved on ...

After falling 17 per cent since the start of the year to its March lows, the stock of the country’s largest pharmaceutical ...

India’s wealthiest billionaires have lost a staggering $30.5 billion (Rs 2.6 lakh crore) as stock market instability and ...

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Dilip Shanghvi had said in February that the judgment was crucial for Sun Pharma's future course of action on this drug ...

According to the USFDA, a Class II recall is issued when the use of or exposure to a violative product may cause temporary or ...

Sun Pharmaceutical Industries Ltd. closed 13.91% short of its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

Analysts believe the key question is whether India can be exempted from the pharma tariffs, given the better relationship ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

India’s weight loss category is undergoing a dynamic transformation triggered by scientific improvements, pharma innovation, ...

Nifty Pharma index sinks over 2% as Indian drugmakers face tariff heat; Gland, Aurobindo, Biocon, Sun Pharma among top losers ...